Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC.
Kanwal Raghav, MD
person default
Rachel Riechelmann, MD, PhD
Released: October 21, 2021

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

  • Individualizing therapy
  • Clinical data and experience informing optimal dosing
  • Key adverse events

Information on this Educational Activity


Kanwal Raghav, MD

Associate Professor
GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD, has disclosed that he has received funds for research support from Bayer, Daiichi, Medimmune, Merck, and Roche; consulting fess from Bayer and Daiichi; and fees for non-CME/CE services from Daiichi.
Rachel Riechelmann, MD, PhD

Director, Clinical Oncology
AC Camargo Cancer Center
Sao Paulo, Brazil

Rachel Riechelmann, MD, PhD, has disclosed that she has received funds for research support from Amgen and consulting fees from Amgen, Bayer, MSD, and Novartis.

Program Medium

This program has been made available online.


Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

In slides from Clinical Care Options (CCO), experts discuss emerging data surrounding use of immune checkpoint inhibitors for early HCC

Amit G. Singal, MD, MS Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.